Aortic Aneurysm Clinical Trial
Official title:
Safety and Effectiveness of Surgeon-Modified Fenestrated and Branched Endografts in Treating Subjects With Complex Aortic Aneurysms
The primary objective of the present study is to evaluate the safety, effectiveness, and clinical outcomes of surgeon-modified fenestrated stent grafts used to treat patients with failed previous infrarenal repairs (failed EVAR) and complex aortic aneurysms (thoracoabdominal, juxtarenal, pararenal, and paravisceral aneurysms).
The study is a prospective, non-randomized evaluation of endovascular repair of patients with failed previous infrarenal repairs (failed EVAR) and complex thoracoabdominal/juxtarenal/pararenal/paravisceral aortic aneurysm repair, including those with penetrating ulcers and aneurysms resulting from aortic dissections, who (1) have anatomy that is not suitable for endovascular repair using grafts currently marketed in the United States, (2) are deemed unsafe to wait the required time necessary for commercial endograft manufacturing, and (3) are at high risk for open surgical repair. Depending on the location of the aneurysm, patients with failed EVAR and complex aortic pathology requiring fenestrated and branched endovascular repair will be treated with physician-modified Cook Zenith devices (Zenith Flex, Zenith Fenestrated stent graft (Zfen), Cook Alpha Thoracic Endovascular Graft, Cook dissection TX2), and their associated commercially approved ancillary components. Whenever possible, the Zenith fenestrated universal bifurcated device will be used for patients requiring repair down to the iliac arteries. The Gore Excluder Endoprosthesis or the Gore Iliac Branch Endoprosthesis (IBE) will be used whenever the Zenith universal bifurcated device is not available. Safety and effectiveness will be assessed acutely (i.e., treatment success and technical success), at 30 days (i.e., the rate of major adverse events (MAE)), at 6 months, at 12 months, and annually to 5 years (i.e., the proportion of treatment group subjects that achieve and maintain treatment success). ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04149600 -
Identification of Genetic Causes of Calcific Aortic Valve Disease
|
||
Enrolling by invitation |
NCT04035356 -
HAART Annuloplasty Device Valve Repair Registry
|
||
Recruiting |
NCT02729064 -
Intraoperative Nasal Insulin Effect on Plasma and CSF Insulin Concentration and Blood Glucose
|
Phase 1 | |
Completed |
NCT02467062 -
Implementation of Non-size Markers Derived From 4D Flow MRI of Patients With Aortic Disease.
|
N/A | |
Completed |
NCT02283307 -
Dual Energy CT Urography With Reduced Iodinated Contrast
|
N/A | |
Completed |
NCT01678261 -
X-chromosome Inactivation, Epigenetics and the Transcriptome
|
N/A | |
Terminated |
NCT01055275 -
Cook Iliac Branch Graft Post-market Registry
|
N/A | |
Completed |
NCT00615888 -
Fast Track Management in Elective Open Infrarenal Aortic Aneurysm Repair
|
N/A | |
Completed |
NCT03510793 -
Microcirculation and Anesthesia in Vascular Surgery
|
||
Completed |
NCT03207568 -
RE-GENERATION: The Safety and Performance of the Relay Pro and Relay NBS Pro Stent-graft Devices in the European Union (EU)
|
N/A | |
Recruiting |
NCT05073991 -
Incidence of Mortality and Complications After Lung Surgery, Open Thoracic Aortic Repair, TEVAR, EVAR.
|
||
Not yet recruiting |
NCT01918982 -
Circulating Endothelial Progenitor Cells and Aortic Aneurysm
|
N/A | |
Not yet recruiting |
NCT01918969 -
Reference Values of Circulating Endothelial Progenitor Cells
|
N/A | |
Completed |
NCT02000544 -
Clinical Evaluation of a Modular Extracorporeal Circulation Circuit
|
N/A | |
Completed |
NCT01256372 -
An Trial of Two Dosing Regimens of AP214 for the Prevention of Kidney Injury in Patients Undergoing Cardiac Surgery
|
Phase 2 | |
Recruiting |
NCT00661518 -
PET/CT Imaging of Aneurysm Wall Inflammation
|
N/A | |
Completed |
NCT00094575 -
Standard Open Surgery Versus Endovascular Repair of Abdominal Aortic Aneurysm (AAA)
|
Phase 4 | |
Recruiting |
NCT04471909 -
NEXUS Aortic Arch Clinical Study to Evaluate Safety and Effectiveness
|
N/A | |
Recruiting |
NCT05603520 -
Phenotyping Heterogeneity and Regionality of the Aorta
|
||
Completed |
NCT03727542 -
Influence of Short AV Delay Permanent Pacing on Matrix Metalloproteinase Levels
|
N/A |